Financial Daily
from THE HINDU group of publications
Thursday, September 20, 2001
|
Financial Daily from THE HINDU group of publications Thursday, September 20, 2001 |
||
|
|
||
|
• AGRI-BUSINESS • CORPORATE • INDUSTRY • LETTERS • MACRO ECONOMY • MARKETS • NEWS • OPINION • VARIETY • INFO-TECH • CATALYST • INVESTMENT WORLD • MONEY & BANKING • LOGISTICS |
Markets
| Next
| Prev
Cadila: Only a fleeting impact
FROM a long-term perspective, Cadila's acquisition of Kopran's cardiovascular drug, Aten, is a positive development.
The drug will help Cadila diversify its portfolio in one of the most lucrative therapeutic segments in the pharmaceutical market. The move, however, is unlikely to have anything more than a fleeting impact on the stock which currently hovers around Rs 10
2. -- BL Research Bureau
|
|
|
Related links: Zydus buys `Aten' for Rs 75 cr Comment on this article to BLFeedback@thehindu.co.in Send this article to Friends by E-Mail
Next: Entertaining show from Zee, Balaji Tele Prev: Kirloskar Bros: Windfall order? Markets Agri-Business | Corporate | Industry | Letters | Macro Economy | Markets | News | Opinion | Variety | Info-Tech | Catalyst | Investment World | Money & Banking | Logistics | Copyright © 2001 The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line. |